Mind Medicine Stock Price, News & Analysis

MindMed (NASDAQ: MNMD) has published groundbreaking Phase 2b clinical trial results in JAMA for MM120 (LSD) in treating Generalized Anxiety Disorder (GAD). The study, involving 198 adults with moderate-to-severe GAD, tested four dose levels (25, 50, 100, or 200 µg) without psychotherapy.

The 100 µg dose showed optimal results, achieving a 7.6-point greater reduction in HAM-A scores versus placebo at Week 4, with 65% clinical response and 48% remission rates sustained through Week 12. The treatment was well-tolerated, with most adverse effects being mild-to-moderate and transient.

Based on these results, the FDA has granted Breakthrough Therapy Designation to MM120 for GAD. MindMed is currently conducting three Phase 3 trials, with topline data expected in 2026.

MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced its participation in four major investor conferences in September 2025. The company will engage in fireside chat presentations at the Cantor Global Healthcare Conference (Sept 5), H.C. Wainwright Global Investment Conference (Sept 9), Baird Global Healthcare Conference (Sept 10), and TD Cowen's Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (Sept 18).

The presentations will be available via webcast on MindMed's Investor Relations website, with replays accessible for up to 90 days after each event.

MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced new employee inducement grants. The company issued 425,450 stock options and 34,500 performance share units (PSUs) to five newly hired non-executive employees.

The stock options will vest over four years, with 25% vesting in the first year and the remaining 75% vesting monthly over three years. The PSUs will vest on the third anniversary of the grant date, with potential earnings ranging from 0% to 200% based on performance metrics. These grants were approved by MindMed's Compensation Committee and issued under NASDAQ Rule 5635(c)(4).

MindMed (NASDAQ: MNMD) reported Q2 2025 financial results and business updates, highlighting strong progress in its clinical trials. The company is advancing three pivotal Phase 3 trials of MM120 ODT for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD), with data expected in 2026. Cash position stands at $237.9 million, sufficient to fund operations into 2027.

Key financial metrics include R&D expenses of $29.8 million (up from $14.6M YoY) and a net loss of $42.7 million (compared to $5.9M in Q2 2024). The company strengthened its leadership team by appointing Brandi L. Roberts as CFO and continues to show strong enrollment across all clinical trials, with Phase 3 Voyage trial data anticipated in 1H 2026, followed by Panorama and Emerge trials in 2H 2026.

MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has scheduled its Q2 2025 financial results webcast for July 31, 2025, at 4:30 p.m. EDT. The company will present its financial performance for the quarter ended June 30, 2025, along with recent business updates.

The presentation will include a Q&A session for analysts, and participants are advised to join 15 minutes before the start time. A replay will be available on MindMed's investor relations website for at least 30 days following the event.

MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has granted stock options to six new non-executive employees. The inducement grants total 96,400 common shares with grant dates of July 7 and July 14, 2025.

The options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years. The exercise price is set at the closing price of MindMed shares on the respective grant dates. These grants were approved by MindMed's Compensation Committee on June 26, 2025, in compliance with NASDAQ Rule 5635(c)(4).

MindMed (NASDAQ: MNMD) has announced the issuance of inducement grants to four new non-executive employees. The grants consist of options to purchase 128,750 common shares, with grant dates of June 2 and June 9, 2025. The exercise price is set at the closing price of MindMed's shares on the last trading day before each grant. The options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in monthly increments over the following three years, contingent on continued employment. These grants were approved by MindMed's Compensation Committee on May 29, 2025, as material inducement to employment, following NASDAQ Rule 5635(c)(4), and were issued outside the company's regular equity incentive plans.

MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced its participation in two upcoming investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 12:50 PM ET in New York. Additionally, MindMed will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference on June 17, 2025, at 7:00 AM ET. Audio webcasts and replays will be available on MindMed's Investor Relations website for 90 days after each event.

MindMed (NASDAQ: MNMD) has appointed Brandi L. Roberts as Chief Financial Officer, effective June 2, 2025. Roberts brings over 25 years of financial leadership experience in life sciences, most recently serving as CFO at Longboard Pharmaceuticals where she led the company through its IPO and $2.6 billion acquisition by Lundbeck in 2024. In her new role, she will oversee financial strategy, capital planning, accounting, investor relations, and IT operations as MindMed advances MM120 ODT for generalized anxiety disorder and major depressive disorder. As part of her compensation package, Roberts will receive inducement awards including an option to purchase 500,000 common shares and 125,000 performance share units that can range from 0%-200% based on performance metrics.